• Figitumumab ELISA Kit
1 1

AntibodySystem

KDC29903

Figitumumab ELISA Kit

Figitumumab ELISA Kit

Title

Catalog No.: KDC29903

Catalog No. KDC29903
Product name Figitumumab ELISA Kit
Size 96 T
Description PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD221 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Figitumumab in the sample competitively binds to the pre-coated protein with biotin-labeled Figitumumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Figitumumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications Used for the quantitative determination of Figitumumab concentration in serum and plasma.
Stability and Storage When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Detection method Colorimetric
Precision CV<20%
Sample type Plasma, Serum
Assay type Quantitative
Sensitivity 10.24 ng/mL
Range 62.5 - 4,000 ng/mL
Recovery 80-120%
Background Figitumumab is a fully humanized IgG2 mAb against IGF-1R. Its recommended dose is 20 mg/kg repeated weekly. In phase I trials treatment-related toxicities were generally mild. The most common adverse events reported were hyperglycemia, anorexia, nausea, elevation of liver function tests, diarrhea, hyperuracemia and fatigue. Figitumumab had shown significant activity against non-small-cell lung cancer (NSCLC) and it was planned to be evaluated in combination with chemotherapy in a randomized phase III trial in patients with metastatic NSCLC. However, the study was early discontinued on December 2009 because an independent monitoring committee concluded that the combination of figitumumab plus chemotherapy would be unlikely to meet the primary endpoint of improving overall survival compared to chemotherapy alone. Additionally, there were also some concerns that hyperglycemia could be a potential contributor of increased patients’ morbidity. In regard to breast cancer, figitumumab was planned to be tested in phase I trials as neo-adjuvant treatment, but the trial was withdrawn prior initiation, although there are preclinical data showing a additive and/or synergistic effect of figitumumab with chemotherapy in basal breast cancer subtype.
Alternative Names CP-751871, CAS: 943453-46-1
Shipping 2-8 ℃
Note For Research Use Only.
전체 세부 정보 보기